Shang S, Liu J, Verma V, et al. Combined treatment of non-small cell lung cancer using radiotherapy and immunotherapy: challenges and updates. Cancer Commun (Lond). 2021;41:1086–99.

Article  PubMed  Google Scholar 

Naimi A, Mohammed RN, Raji A, et al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal. 2022;20:44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377:1919–29.

Article  CAS  PubMed  Google Scholar 

Spigel DR, Faivre-Finn C, Gray JE, et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022;40:1301–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Paz-Ares L, Spira A, Raben D, et al. Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial. Ann Oncol. 2020;31:798–806.

Article  CAS  PubMed  Google Scholar 

Haratani K, Nakamura A, Mamesaya N, et al. Tumor Microenvironment Landscape of NSCLC Reveals Resistance Mechanisms for Programmed Death-Ligand 1 Blockade After Chemoradiotherapy: A Multicenter Prospective Biomarker Study (WJOG11518L:SUBMARINE). J Thorac Oncol. 2023;18:1334–50.

Article  CAS  PubMed  Google Scholar 

Wang D, Qiu B, He H, et al. Tumor response evaluation by combined modalities of chest magnetic resonance imaging and computed tomography in locally advanced non-small cell lung cancer after concurrent chemoradiotherapy. Radiother Oncol. 2022;168:211–20.

Article  CAS  PubMed  Google Scholar 

Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:e143–52.

Article  PubMed  PubMed Central  Google Scholar 

Won SE, Park HJ, Byun S, et al. Impact of pseudoprogression and treatment beyond progression on outcome in patients with non-small cell lung cancer treated with immune checkpoint inhibitors. Oncoimmunology. 2020;9:1776058.

Article  PubMed  PubMed Central  Google Scholar 

Ramon-Patino JL, Schmid S, Lau S, et al. iRECIST and atypical patterns of response to immuno-oncology drugs. J Immunother Cancer. 2022;10(6):e004849.

Leger MA, Routy B, Juneau D. FDG PET/CT for Evaluation of Immunotherapy Response in Lung Cancer Patients. Semin Nucl Med. 2022;52:707–19.

Article  PubMed  Google Scholar 

Rossi G, Bauckneht M, Genova C, et al. Comparison Between (18)F-FDG PET-Based and CT-Based Criteria in Non-Small Cell Lung Cancer Patients Treated with Nivolumab. J Nucl Med. 2020;61:990–8.

Article  CAS  PubMed  Google Scholar 

Cheng Y, Chen ZY, Huang JJ, Shao D. Efficacy evaluation of neoadjuvant immunotherapy plus chemotherapy for non-small-cell lung cancer: comparison of PET/CT with postoperative pathology. Eur Radiol. 2023;33:6625–35.

Article  CAS  PubMed  Google Scholar 

Humbert O, Cadour N, Paquet M, et al. (18)FDG PET/CT in the early assessment of non-small cell lung cancer response to immunotherapy: frequency and clinical significance of atypical evolutive patterns. Eur J Nucl Med Mol Imaging. 2020;47:1158–67.

Article  CAS  PubMed  Google Scholar 

Mitchell KG, Amini B, Wang Y, et al. (18)F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. Cancer Immunol Immunother. 2020;69:1519–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Katal S, Eibschutz LS, Saboury B, et al. Advantages and applications of total-body PET scanning. Diagnostics (Basel). 2022;12(2):426.

Article  PubMed  PubMed Central  Google Scholar 

Nadig V, Herrmann K, Mottaghy FM, Schulz V. Hybrid total-body pet scanners-current status and future perspectives. Eur J Nucl Med Mol Imaging. 2022;49:445–59.

Article  PubMed  Google Scholar 

Cherry SR, Jones T, Karp JS, et al. Total-Body PET: Maximizing Sensitivity to Create New Opportunities for Clinical Research and Patient Care. J Nucl Med. 2018;59:3–12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu G, Hu P, Yu H, et al. Ultra-low-activity total-body dynamic PET imaging allows equal performance to full-activity PET imaging for investigating kinetic metrics of (18)F-FDG in healthy volunteers. Eur J Nucl Med Mol Imaging. 2021;48:2373–83.

Article  PubMed  Google Scholar 

Wang D, Qiu B, Liu Q, et al. Patlak-Ki derived from ultra-high sensitivity dynamic total body [(18)F]FDG PET/CT correlates with the response to induction immuno-chemotherapy in locally advanced non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging. 2023;50:3400–13.

Article  CAS  PubMed  Google Scholar 

Zhou R, Qiu B, Xiong M, et al. Hypofractionated Radiotherapy followed by Hypofractionated Boost with weekly concurrent chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Results of A Prospective Phase II Study (GASTO-1049). Int J Radiat Oncol Biol Phys. 2023;117:387–99.

Article  PubMed  Google Scholar 

Dimitrakopoulou-Strauss A, Strauss LG, Burger C, et al. Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy. J Nucl Med. 2004;45:1480–7.

CAS  PubMed  Google Scholar 

Epelbaum R, Frenkel A, Haddad R, et al. Tumor aggressiveness and patient outcome in cancer of the pancreas assessed by dynamic 18F-FDG PET/CT. J Nucl Med. 2013;54:12–8.

Article  CAS  PubMed  Google Scholar 

Dimitrakopoulou-Strauss A, Strauss LG, Egerer G, et al. Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysis. Eur J Nucl Med Mol Imaging. 2010;37:1481–9.

Article  CAS  PubMed  Google Scholar 

Kazerouni AS, Peterson LM, Jenkins I, et al. Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer. Breast Cancer Res. 2023;25:138.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hylton NM, Gatsonis CA, Rosen MA, et al. Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL. Radiology. 2016;279:44–55.

Article  PubMed  Google Scholar 

Wang Y, Zhao N, Wu Z, et al. New insight on the correlation of metabolic status on (18)F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2020;47:1127–36.

Article  PubMed  Google Scholar 

Wang D, Zhang X, Liu H, et al. Assessing dynamic metabolic heterogeneity in non-small cell lung cancer patients via ultra-high sensitivity total-body [(18)F]FDG PET/CT imaging: quantitative analysis of [(18)F]FDG uptake in primary tumors and metastatic lymph nodes. Eur J Nucl Med Mol Imaging. 2022;49:4692–704.

Article  CAS  PubMed  Google Scholar 

Borm FJ, Smit J, Bakker J, et al. Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodes. Oncoimmunology. 2023;12:2204745.

Article  PubMed  PubMed Central  Google Scholar 

Lopci E, Toschi L, Grizzi F, et al. Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. Eur J Nucl Med Mol Imaging. 2016;43:1954–61.

Article  CAS  PubMed  Google Scholar 

Buder-Bakhaya K, Hassel JC. Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond. Front Immunol. 2018;9:1474.

Article  PubMed  P